Wire · founder news, decoded · opportunities
How 1st FDA approved once-a-day pill to lower 'bad' cholesterol could shift treatment from statins
The FDA has approved Lipfendra (enlicitide), the first oral PCSK9 inhibitor pill for lowering LDL cholesterol, offering a pill-based alternative to injectable cholesterol treatments for patients whose cholesterol remains high despite statins. The drug reduced LDL by 56-59% in trials and targets high-risk patients including those with diabetes, inherited hypercholesterolaemia, and prior heart disease.
The Wire takeaway
If you're building adherence tools, compliance software, or patient engagement platforms for chronic disease, you just watched a category (injectable cholesterol drugs) become a tablet category. Merck's shift from injection to pill on a proven molecule is a playbook: find where needle anxiety or inconvenience kills adoption, then solve it with formulation. That gap is your wedge.
Read the full story at theprint.in →
Topics: Digital Health · cardiovascular-drugs · oral-formulation-shift · pcsk9-inhibitors · merck · regulatory-approval · patient-adherence